[1]于 伟,李佳宁,钟 璐,等.中医优势病种按疗效价值付费改革效果分析[J].卫生经济研究,2025,42(04):23-27.
　YU Wei,LI Jianing,ZHONG Lu,et al.Analysis of the Effect of the Payment Reform according to the Value of Efficacy for Dominant Diseases in Traditional Chinese Medicine[J].Journal Press of Health Economics Research,2025,42(04):23-27.
点击复制

中医优势病种按疗效价值付费改革效果分析
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
42
期数:
2025年04期
页码:
23-27
栏目:
改革探索
出版日期:
2025-04-02

文章信息/Info

Title:
Analysis of the Effect of the Payment Reform according to the Value of Efficacy for Dominant Diseases in Traditional Chinese Medicine
作者:
于 伟1; 李佳宁1; 钟 璐2; 黄 伟3; 叶子轶4; 李昀梦5; 曾雪琴4
1.西南医科大学附属医院，四川 泸州 646000
2.蓬安县中医医院，四川 南充 637800
3.泸州市医疗保障事务中心，四川 泸州 646000
4.西南医科大学，四川 泸州 646000
5.营山县中医医院，四川 南充 637700
Author(s):
YU Wei;  LI Jianing;  ZHONG Lu;  HUANG Wei;  YE Ziyi;  LI Yunmeng;  ZENG Xueqin
The Affiliated Hospital of Southwest Medical University，Luzhou Sichuan 646000，China
关键词:
中医优势病种; 按疗效价值付费; 按病种付费
Keywords:
dominant diseases in traditional Chinese medicine;  payment according to the value of efficacy;  DIP
分类号:
R197
文献标志码:
A
摘要:
目的：分析中医优势病种按疗效价值付费改革效果，为改革向纵深推进提供参考。方法：采用双重差分模型（DID），对泸州市10个按疗效价值付费的中医优势病种，从资源消耗、费用结构等方面分析中医治疗组（干预组）与手术治疗组（对照组）在改革前后的差异。结果：改革后试点病种采用中医治疗的比例从66.09%提高至71.74%，中医治疗组次均费用、自付费用远低于手术治疗组；除4个指标外，其余指标的DID交互系数均有统计学意义；试点病种的医保结算均处于盈余状态，有8个病种的医保结余空间均为正。结论：中医优势病种按疗效价值付费能够提高中医治疗比例、减轻患者费用负担、提高医疗机构盈余水平、节省医保基金支出；建议逐步扩大试点病种和试点医疗机构范围，完善试点病种临床路径，加强监管与评估，动态调整试点病种支付标准，实现医患保多方共赢。
Abstract:
Objective To analyze the effect of the payment reform according to the value of efficacy for dominant diseases in traditional Chinese medicine, and to provide reference for the reform to be pushed forward in depth. Methods Using the double difference model (DID) method, the differences in resource consumption and cost structure between the TCM group(intervention group) and the surgical treatment group(control group) before and after the reform were analyzed for 10 dominant diseases in traditional Chinese medicine paid according to their value of efficacy in Luzhou City. Results The proportion of pilot diseases treated with TCM increased from 66.09% to 71.74% after the reform, and the sub-average cost and out-of-pocket expenses of the TCM treatment group were much lower than those of the surgical treatment group. Except for the four indicators, the DID interaction coefficients of the other indicators were statistically significant. The medical insurance settlements of the pilot diseases were in a surplus state, and the space of the balance of the medical insurance of eight diseases were all positive. Conclusion The payment reform according to the value of efficacy for dominant diseases in traditional Chinese medicine can increase the proportion of TCM treatment, reduce the cost burden of patients, improve the surplus level of medical institutions, and save the expenditure of medical insurance funds. It is recommended to gradually expand the scope of pilot diseases and pilot medical institutions, improve the clinical pathway of pilot diseases, strengthen the supervision and evaluation, and dynamically adjust the pilot disease payment standard, so as to realize the win-win situation for doctors, patients and insurers.

参考文献/References:

[1] 杨菁，李梦滢，沈际勇.中医优势病种支付方式改革试点经验与启示[J].卫生经济研究，2023，40（12）：33-38.
[2] 廖藏宜，秦纪华，蓝志成.中医优势病种按疗效价值付费的柳州经验[J].卫生经济研究，2023，40（06）：61-63，67.
[3] 岳铭坤，李凯，黄娜，等.按病种付费对中医优势病种住院费用的影响研究——基于PSM-DID法[J].卫生经济研究，2024，41（03）：62-64.
[4] 郭慧君，刘晶，胡广宇，等.基于双重差分法的DRG付费对中医医院的影响研究[J].中国卫生政策研究，2024，17（06）：47-55.
[5] 黄成凤，申丽君，杨燕绥.价值导向型医保付费政策效果探讨——基于柳州市中医优势病种的实证分析[J].卫生经济研究，2022，39（05）：37-41.
[6] 黄炜，张子尧，刘安然.从双重差分法到事件研究法[J].产业经济评论，2022（02）：17-36.
[7] 陈明波，梁沛枫.DRG/DIP支付方式改革下开展中医优势病种的思考[J].中国医院，2024，28（09）：12-14.

相似文献/References:

[1]张 弘,丁 科,谢俊明,等.“疗效价值付费”下的中医优势病种DRG付费方案探索[J].卫生经济研究,2021,38(12):75.
　ZHANG Hong,DING Ke,XIE Jun-ming,et al.Exploration of DRG Payment Scheme for Dominant Diseases of Traditional Chinese Medicine under "Efficacy Value Payment"[J].Journal Press of Health Economics Research,2021,38(04):75.
[2]李祖兰,周戈耀,毛 佳,等.贵州省中医优势病种支付方式改革推行的影响因素研究[J].卫生经济研究,2023,40(10):61.
　LI Zulan,ZHOU Geyao,MAO Jia,et al.Study on the Influencing Factors of the Implementation of Payment Reform for Dominant Diseases of Traditional Chinese Medicine in Guizhou Province[J].Journal Press of Health Economics Research,2023,40(04):61.
[3]杨 菁,李梦滢,沈际勇.中医优势病种支付方式改革试点经验与启示[J].卫生经济研究,2023,40(12):33.
　YANG Jing,LI Mengying,SHEN Jiyong.Experience and Enlightenment of the Pilot Reform of Payment Methods for Dominant Diseases of Traditional Chinese Medicine[J].Journal Press of Health Economics Research,2023,40(04):33.
[4]岳铭坤,李 凯,黄 娜,等.按病种付费对中医优势病种住院费用的影响研究 ——基于PSM-DID法[J].卫生经济研究,2024,41(03):62.
　YUE Mingkun,LI Kai,HUANG Na,et al.Study the Impact of DRG on the Hospitalization Expenses of the Dominant Diseases of Traditional Chinese Medicine ——Based on PSM-DID Method[J].Journal Press of Health Economics Research,2024,41(04):62.
[5]李 希,邓世虎,彭美华,等.中医优势病种DRG付费：政策、难点及对策[J].卫生经济研究,2025,42(01):39.
　LI Xi,DENG Shihu,PENG Meihua,et al.DRG Payment for Dominant Diseases of Traditional Chinese Medicine: Policies, Difficulties and Countermeasures[J].Journal Press of Health Economics Research,2025,42(04):39.
[6]黄成凤,申丽君,杨燕绥.价值导向型医保付费政策效果探讨——基于柳州市中医优势病种的实证分析[J].卫生经济研究,2022,39(5):37.
　HUANG Cheng-feng,SHEN Li-jun,YANG Yan-sui.Discussion on the Effect of Value-Oriented Medical Insurance Payment Policy ——Based on Empirical Analysis in Liuzhou[J].Journal Press of Health Economics Research,2022,39(04):37.
[7]廖藏宜,秦纪华,蓝志成.中医优势病种按疗效价值付费的柳州经验[J].卫生经济研究,2023,40(6):61.
　LIAO Zangyi,QIN Jihua,LAN Zhicheng.Experience of Efficacy Value Payment for Dominant Diseases of Traditional Chinese Medicine in Liuzhou[J].Journal Press of Health Economics Research,2023,40(04):61.

更新日期/Last Update: 2025-04-02